

Dyspepsia Market Report and Forecast 2024-2032

Market Report (7 days) | 2024-02-01 | 180 pages | EMR Inc.

AVAILABLE LICENSES:

- Single User License \$5499.00
- Five User License \$7499.00
- Corporate License \$9499.00

Report description:

Dyspepsia Market Report and Forecast 2024-2032

Dyspepsia Market Outlook

The dyspepsia market size is anticipated to grow at a CAGR of 8.4% during the forecast period of 2024-2032, driven by the growing emphasis on personalized or precision medicine in disease management across the major markets.

Dyspepsia: Introduction

Dyspepsia, commonly known as indigestion, is a condition characterized by chronic or recurrent discomfort in the upper abdomen. Symptoms may include bloating, nausea, belching, and a feeling of fullness or pain after eating. Dyspepsia can result from various causes, including gastritis, peptic ulcers, gastroesophageal reflux disease (GERD), or functional (non-ulcer) dyspepsia, where no clear cause is found. Management typically involves lifestyle modifications, dietary changes, and medications such as antacids, proton pump inhibitors, or H2-receptor antagonists to relieve symptoms.

Key Trends in the Dyspepsia Market

There's a growing trend towards increased awareness of dyspepsia symptoms and self-management practices. Over-the-counter (OTC) medications for symptom relief are in high demand, with consumers seeking immediate and accessible remedies.

As the understanding of the impact of lifestyle and diet on dyspepsia grows, there's a noticeable shift towards non-pharmacological interventions. This includes dietary modifications, stress reduction techniques, and lifestyle changes as first-line management strategies.

The market is gradually moving towards personalized treatment approaches in managing dyspepsia, especially for cases related to specific underlying conditions like H. pylori infection, GERD, or peptic ulcer disease. This trend is driven by advancements in diagnostic technologies and a better understanding of the pathophysiology of dyspepsia.

There's ongoing research and development of new pharmaceuticals targeting the underlying causes of dyspepsia and improving symptom management. This includes the development of drugs with novel mechanisms of action, such as prokinetics and agents that target the gut-brain axis.

Integration of Digital Health Solutions: Digital health technologies, including apps for diet tracking and stress management, are becoming more integrated into the management of dyspepsia. These tools help patients monitor their symptoms, manage their condition more effectively, and adhere to treatment plans.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Emerging research on the gut microbiome's role in various gastrointestinal disorders, including dyspepsia, is influencing treatment approaches. Probiotics and dietary supplements aimed at restoring gut microbiome balance are gaining popularity as complementary therapies.

Dyspepsia Market Segmentation

Market Breakup by Diagnosis

- Blood Tests
- Stool Tests
- Breath Tests
- Endoscopy
- X-Ray
- CT Scan
- Others

Market Breakup by Type

- Organic Dyspepsia
- Non-Ulcer Dyspepsia
- Drug Induced Dyspepsia
- Others

Market Breakup by Indication

- Functional Dyspepsia
- Organic Dyspepsia

Market Breakup by Treatment

- Proton Pump Inhibitors
- H2 Blockers
- Antacids
- Antibiotics
- Prokinetics
- Antidepressants

Market Breakup by Treatment Type

- Medication
- Surgery

Market Breakup by Drug Type

- Branded
- Generic

Market Breakup by Route of Administration

- Oral
- Injectable

Market Breakup by Region

- United States
- EU-4 and the United Kingdom
 - o□ Germany
 - o□ France
 - o□ Italy
 - o□ Spain
 - o□ United Kingdom
- Japan
- China

Dyspepsia Market Overview

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

In North America, the dyspepsia market is driven by a high prevalence of gastrointestinal disorders and a significant focus on digestive health. Lifestyle factors and dietary habits contribute to the demand for treatment options. The market includes a wide range of over-the-counter (OTC) and prescription medications, alongside a growing interest in probiotics and dietary supplements for symptom management. There's also an emphasis on personalized treatment approaches and non-pharmacological interventions, such as dietary modifications and stress management techniques.

Europe's market is characterized by strong healthcare systems and an emphasis on evidence-based treatments for dyspepsia. Public health initiatives aimed at improving dietary habits and reducing alcohol and tobacco consumption impact market dynamics. The availability of OTC medications is high, and there's a notable interest in natural and alternative remedies. Regulatory frameworks support rigorous testing and approval processes for new treatments, ensuring patient safety and treatment efficacy.

In Japan, the dyspepsia market reflects the country's high regard for gastrointestinal health, with a wide acceptance of both modern and traditional treatments. Japanese consumers show a strong preference for products with natural ingredients and traditional medicines alongside conventional treatments. The market is supported by advanced healthcare research, leading to the development of innovative therapeutics. Public health campaigns focusing on healthy eating and lifestyle habits also play a crucial role in managing dyspepsia symptoms.

Dyspepsia Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players.

- Bayer AG
- Mankind Pharma
- Cadila Pharmaceuticals
- Salix Pharmaceuticals
- Sanofi
- Aosaikand Pharmaceutical Co., Ltd
- Hanmi Pharm. Co.
- Lupin
- RedHill Biopharma Ltd.
- Abbott.
- GlaxoSmithKline
- Johnson&Johnson
- Eisai Co Ltd
- AstraZeneca
- Allergen Plc

We at Expert Market Research always strive to provide you with the latest information. The numbers in the article are only indicative and may be different from the actual report.

Table of Contents:

- 1 Preface
 - 1.1 Objectives of the Study
 - 1.2 Key Assumptions
 - 1.3 Report Coverage - Key Segmentation and Scope
 - 1.4 Research Methodology
- 2 Executive Summary

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 3 Dyspepsia Overview
 - 3.1 Guidelines and Stages
 - 3.2 Pathophysiology
 - 3.3 Screening and Drug
 - 3.4 Treatment Pathway
- 4 Patient Profile
 - 4.1 Patient Profile Overview
 - 4.2 Patient Psychology and Emotional Impact Factors
 - 4.3 Risk Assessment and Treatment Success Rate
- 5 Dyspepsia Epidemiology Analysis - 7MM
 - 5.1 7MM Epidemiology Scenario Overview (2017-2032)
 - 5.2 United States Dyspepsia Epidemiology Forecast (2017-2032)
 - 5.3 EU-4 and United Kingdom Dyspepsia Epidemiology Forecast (2017-2032)
 - 5.3.1 Germany Dyspepsia Epidemiology Forecast (2017-2032)
 - 5.3.2 France Dyspepsia Epidemiology Forecast (2017-2032)
 - 5.3.3 Italy Dyspepsia Epidemiology Forecast (2017-2032)
 - 5.3.4 Spain Dyspepsia Epidemiology Forecast (2017-2032)
 - 5.3.5 United Kingdom Dyspepsia Epidemiology Forecast (2017-2032)
 - 5.4 Japan Dyspepsia Epidemiology Forecast (2017-2032)
- 6 Dyspepsia Market Overview - 7MM
 - 6.1 Dyspepsia Market Historical Value (2017-2023)
 - 6.2 Dyspepsia Market Forecast Value (2024-2032)
- 7 Dyspepsia Market Landscape - 7MM
 - 7.1 Dyspepsia: Developers Landscape
 - 7.1.1 Analysis by Year of Establishment
 - 7.1.2 Analysis by Company Size
 - 7.1.3 Analysis by Region
 - 7.2 Dyspepsia Product Landscape
 - 7.2.1 Analysis by Indication
 - 7.2.2 Analysis by Drug Type
- 8 Dyspepsia Challenges and Unmet Needs
 - 8.1 Treatment Pathway Challenges
 - 8.2 Compliance and Drop-Out Analysis
 - 8.3 Awareness and Prevention Gaps
- 9 Cost of Treatment
- 10 Dyspepsia Market Dynamics
 - 10.1 Market Drivers and Constraints
 - 10.2 SWOT Analysis
 - 10.3 Porter's Five Forces Model
 - 10.4 Key Demand Indicators
 - 10.5 Key Price Indicators
 - 10.6 Industry Events, Initiatives, and Trends
 - 10.7 Value Chain Analysis
- 11 Dyspepsia Market Segmentation - 7MM
 - 11.1 Dyspepsia Market by Diagnosis
 - 11.1.1 Market Overview
 - 11.1.2 Blood Tests

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 11.1.3 Stool Tests
- 11.1.4 Breath Tests
- 11.1.5 Endoscopy
- 11.1.6 X-Ray
- 11.1.7 CT Scan
- 11.1.8 Others
- 11.2 Dyspepsia Market by Type
 - 11.2.1 Market Overview
 - 11.2.2 Organic Dyspepsia
 - 11.2.3 Non-Ulcer Dyspepsia
 - 11.2.4 Drug Induced Dyspepsia
 - 11.2.5 Others
- 11.3 Dyspepsia Market by Indication
 - 11.3.1 Market Overview
 - 11.3.2 Functional Dyspepsia
 - 11.3.3 Organic Dyspepsia
- 11.4 Dyspepsia Market by Treatment
 - 11.4.1 Market Overview
 - 11.4.2 Proton Pump Inhibitors
 - 11.4.3 H2 Blockers
 - 11.4.4 Antacids
 - 11.4.5 Antibiotics
 - 11.4.6 Prokinetics
 - 11.4.7 Antidepressants
- 11.5 Dyspepsia Market by Treatment Type
 - 11.5.1 Market Overview
 - 11.5.2 Medication
 - 11.5.3 Surgery
- 11.6 Dyspepsia Market by Drug Type
 - 11.6.1 Market Overview
 - 11.6.2 Branded
 - 11.6.3 Generic
- 11.7 Dyspepsia Market by Route of Administration
 - 11.7.1 Market Overview
 - 11.7.2 Oral
 - 11.7.3 Injectable
- 11.8 Dyspepsia Market by Region
 - 11.8.1 Market Overview
 - 11.8.2 United States
 - 11.8.3 EU-4 and the United Kingdom
 - 11.8.3.1 Germany
 - 11.8.3.2 France
 - 11.8.3.3 Italy
 - 11.8.3.4 Spain
 - 11.8.3.5 United Kingdom
 - 11.8.4 Japan
- 12 United States Dyspepsia Market

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 12.1 Dyspepsia Market Historical Value (2017-2023)
- 12.2 Dyspepsia Market Forecast Value (2024-2032)
- 12.3 Dyspepsia Market by Diagnosis
- 12.4 Dyspepsia Market by Indication
- 13 EU-4 and United Kingdom Dyspepsia Market
 - 13.1 Dyspepsia Market Historical Value (2017-2023)
 - 13.2 Dyspepsia Market Forecast Value (2024-2032)
 - 13.3 Germany Dyspepsia Market Overview
 - 13.3.1 Dyspepsia Market by Diagnosis
 - 13.3.2 Dyspepsia Market by Indication
 - 13.4 France Dyspepsia Market Overview
 - 13.4.1 Dyspepsia Market by Diagnosis
 - 13.4.2 Dyspepsia Market by Indication
 - 13.5 Italy Dyspepsia Market Overview
 - 13.5.1 Dyspepsia Market by Diagnosis
 - 13.5.2 Dyspepsia Market by Indication
 - 13.6 Spain Dyspepsia Market Overview
 - 13.6.1 Dyspepsia Market by Diagnosis
 - 13.6.2 Dyspepsia Market by Indication
 - 13.7 United Kingdom Dyspepsia Market Overview
 - 13.7.1 Dyspepsia Market by Diagnosis
 - 13.7.2 Dyspepsia Market by Indication
- 14 Japan Dyspepsia Market
 - 14.1 Dyspepsia Market Historical Value (2017-2023)
 - 14.2 Dyspepsia Market Forecast Value (2024-2032)
 - 14.3 Dyspepsia Market by Diagnosis
 - 14.4 Dyspepsia Market by Indication
- 15 Regulatory Framework
 - 15.1 Regulatory Overview
 - 15.1.1 US FDA
 - 15.1.2 EU EMA
 - 15.1.3 JAPAN PMDA
- 16 Patent Analysis
 - 16.1 Analysis by Type of Patent
 - 16.2 Analysis by Publication year
 - 16.3 Analysis by Issuing Authority
 - 16.4 Analysis by Patent Age
 - 16.5 Analysis by CPC Analysis
 - 16.6 Analysis by Patent Valuation
 - 16.7 Analysis by Key Players
- 17 Grants Analysis
 - 17.1 Analysis by year
 - 17.2 Analysis by Amount Awarded
 - 17.3 Analysis by Issuing Authority
 - 17.4 Analysis by Grant Application
 - 17.5 Analysis by Funding Institute
 - 17.6 Analysis by NIH Departments

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 17.7 Analysis by Recipient Organization
- 18 Clinical Trials Analysis
 - 18.1 Analysis by Trial Registration Year
 - 18.2 Analysis by Trial Status
 - 18.3 Analysis by Trial Phase
 - 18.4 Analysis by Therapeutic Area
 - 18.5 Analysis by Geography
- 19 Funding and Investment Analysis
 - 19.1 Analysis by Funding Instances
 - 19.2 Analysis by Type of Funding
 - 19.3 Analysis by Funding Amount
 - 19.4 Analysis by Leading Players
 - 19.5 Analysis by Leading Investors
 - 19.6 Analysis by Geography
- 20 Partnerships and Collaborations Analysis
 - 20.1 Analysis by Partnership Instances
 - 20.2 Analysis by Type of Partnership
 - 20.3 Analysis by Leading Players
 - 20.4 Analysis by Geography
- 21 Supplier Landscape
 - 21.1 Bayer AG
 - 21.1.1 Financial Analysis
 - 21.1.2 Product Portfolio
 - 21.1.3 Demographic Reach and Achievements
 - 21.1.4 Mergers and Acquisitions
 - 21.1.5 Certifications
 - 21.2 Mankind Pharma
 - 21.2.1 Financial Analysis
 - 21.2.2 Product Portfolio
 - 21.2.3 Demographic Reach and Achievements
 - 21.2.4 Mergers and Acquisitions
 - 21.2.5 Certifications
 - 21.3 Cadila Pharmaceuticals
 - 21.3.1 Financial Analysis
 - 21.3.2 Product Portfolio
 - 21.3.3 Demographic Reach and Achievements
 - 21.3.4 Mergers and Acquisitions
 - 21.3.5 Certifications
 - 21.4 Salix Pharmaceuticals
 - 21.4.1 Financial Analysis
 - 21.4.2 Product Portfolio
 - 21.4.3 Demographic Reach and Achievements
 - 21.4.4 Mergers and Acquisitions
 - 21.4.5 Certifications
 - 21.5 Sanofi
 - 21.5.1 Financial Analysis
 - 21.5.2 Product Portfolio

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 21.5.3 Demographic Reach and Achievements
- 21.5.4 Mergers and Acquisitions
- 21.5.5 Certifications
- 21.6 Aosaikand Pharmaceutical Co., Ltd
 - 21.6.1 Financial Analysis
 - 21.6.2 Product Portfolio
 - 21.6.3 Demographic Reach and Achievements
 - 21.6.4 Mergers and Acquisitions
 - 21.6.5 Certifications
- 21.7 Hanmi Pharm. Co.
 - 21.7.1 Financial Analysis
 - 21.7.2 Product Portfolio
 - 21.7.3 Demographic Reach and Achievements
 - 21.7.4 Mergers and Acquisitions
 - 21.7.5 Certifications
- 21.8 Lupin
 - 21.8.1 Financial Analysis
 - 21.8.2 Product Portfolio
 - 21.8.3 Demographic Reach and Achievements
 - 21.8.4 Mergers and Acquisitions
 - 21.8.5 Certifications
- 21.9 RedHill Biopharma Ltd.
 - 21.9.1 Financial Analysis
 - 21.9.2 Product Portfolio
 - 21.9.3 Demographic Reach and Achievements
 - 21.9.4 Mergers and Acquisitions
 - 21.9.5 Certifications
- 21.10 Abbott.
 - 21.10.1 Financial Analysis
 - 21.10.2 Product Portfolio
 - 21.10.3 Demographic Reach and Achievements
 - 21.10.4 Mergers and Acquisitions
 - 21.10.5 Certifications
- 21.11 GlaxoSmithKline
 - 21.11.1 Financial Analysis
 - 21.11.2 Product Portfolio
 - 21.11.3 Demographic Reach and Achievements
 - 21.11.4 Mergers and Acquisitions
 - 21.11.5 Certifications
- 21.12 Johnson & Johnson
 - 21.12.1 Financial Analysis
 - 21.12.2 Product Portfolio
 - 21.12.3 Demographic Reach and Achievements
 - 21.12.4 Mergers and Acquisitions
 - 21.12.5 Certifications
- 21.13 Eisai Co Ltd
 - 21.13.1 Financial Analysis

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 21.13.2 Product Portfolio
- 21.13.3 Demographic Reach and Achievements
- 21.13.4 Mergers and Acquisitions
- 21.13.5 Certifications
- 21.14 AstraZeneca
 - 21.14.1 Financial Analysis
 - 21.14.2 Product Portfolio
 - 21.14.3 Demographic Reach and Achievements
 - 21.14.4 Mergers and Acquisitions
 - 21.14.5 Certifications
- 21.15 Allergen Plc
 - 21.15.1 Financial Analysis
 - 21.15.2 Product Portfolio
 - 21.15.3 Demographic Reach and Achievements
 - 21.15.4 Mergers and Acquisitions
 - 21.15.5 Certifications
- 22 Dyspepsia Market- Distribution Model (Additional Insight)
 - 22.1 Overview
 - 22.2 Potential Distributors
 - 22.3 Key Parameters for Distribution Partner Assessment
- 23 Key Opinion Leaders (KOL) Insights (Additional Insight)
- 24 Company Competitiveness Analysis (Additional Insight)
 - 24.1 Very Small Companies
 - 24.2 Small Companies
 - 24.3 Mid-Sized Companies
 - 24.4 Large Companies
 - 24.5 Very Large Companies
- 25 Payment Methods (Additional Insight)
 - 25.1 Government Funded
 - 25.2 Private Insurance
 - 25.3 Out-of-Pocket

*Additional insights provided are customisable as per client requirements.

Dyspepsia Market Report and Forecast 2024-2032

Market Report (7 days) | 2024-02-01 | 180 pages | EMR Inc.

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User License	\$5499.00
	Five User License	\$7499.00
	Corporate License	\$9499.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

☐ ** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2025-05-04"/>
		Signature	<input type="text"/>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com